financetom
Business
financetom
/
Business
/
Senator Warren warns potential BNY merger with Northern Trust may violate federal banking laws
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Senator Warren warns potential BNY merger with Northern Trust may violate federal banking laws
Jul 22, 2025 12:28 PM

WASHINGTON, July 22 (Reuters) - Senator Elizabeth Warren

has warned BNY that its reported interest in a merger

with Northern Trust ( NTRS ) could violate federal banking laws,

saying any potential deal between the two large custody banks

raises antitrust concerns.

Warren, the top Democrat on the Senate Banking Committee and

a longtime big bank critic, told BNY CEO Robin Vince in a letter

sent Tuesday that such a deal, which would combine the world's

largest custody bank with a major competitor, would pose major

financial stability concerns, and asked for a briefing on the

status of potential talks, as well as any ongoing discussions

with regulators.

BNY declined to comment on the letter, and Northern Trust ( NTRS )

did not respond to a request for comment.

"Pursuing a merger that drastically consolidates a key

market while supercharging the firm's risk profile and systemic

importance is irresponsible and may also violate federal banking

laws," she wrote in a letter seen by Reuters.

In June, The Wall Street Journal reported that BNY

approached Northern Trust ( NTRS ) to express interest in a merger,

although Northern Trust ( NTRS ) has said it wants to remain independent.

BNY declined to comment on the original report.

Interest in potential deals between larger banks has been on

the rise as regulators appointed by President Donald Trump have

discussed refining the merger review process after the Biden

administration was cool to transactions among larger firms.

But Warren said such a deal would result in an institution

with a custodial services market share of over 30%, raising

competition concerns and breaching antitrust law.

"Further entrenching its already-dominant market position

would enable BNY to hike fees and increase prices, undermine its

incentives to innovate, erode its customer service, and reduce

the already-limited choices available for institutional clients

looking for custodial services," she wrote.

(Editing by Aurora Ellis)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Oct 10, 2024
09:25 AM EDT, 10/10/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Thursday that volixibat has received breakthrough therapy designation from the US Food and Drug Administration as a potential treatment for cholestatic pruritus related to primary biliary cholangitis. The company said the designation is based on the interim analysis of a phase 2b study that demonstrated statistically significant...
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Oct 10, 2024
09:24 AM EDT, 10/10/2024 (MT Newswires) -- Delta Air Lines ( DAL ) issued a weak fourth-quarter earnings outlook amid expectations for subdued travel demand around the US Presidential elections in November, as the air carrier's bottom line fell short of market estimates in the prior three-month period while revenue beat Wall Street forecasts. The airline anticipates adjusted earnings to...
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Oct 10, 2024
Indivior PLC ( INDV ) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects third-quarter net revenue of $302 million – $309 million versus the consensus of $289.37 million. Also, Indivior ( INDV ) trimmed its FY24 net revenue outlook to $1.125 billion – $1.165 billion (consensus $1.185 billion) from $1.15 billion –...
Starboard seeks probe after former Pfizer execs pull support for its campaign
Starboard seeks probe after former Pfizer execs pull support for its campaign
Oct 10, 2024
(Reuters) - Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday. Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, who were reportedly helping the activist investor in its plan to push...
Copyright 2023-2026 - www.financetom.com All Rights Reserved